I mmediate primary percutaneous coronary intervention (PCI)
is the recommended treatment strategy in patients with STsegment-elevation myocardial infarction (STEMI) to salvage ischemic myocardium and to reduce adverse clinical events. 1, 2 Despite its indisputable beneficial effects, restoration of myocardial blood flow can also jeopardize the myocardium and increase infarct size, a major determinant of outcome in patients with STEMI. [3] [4] [5] [6] [7] Animal models suggest that this reperfusion injury may account for a considerable part of final myocardial damage. 4 Therefore, research efforts sought to prevent or attenuate reperfusion injury and subsequently improve prognosis after STEMI. One of the most promising approaches is ischemic conditioning which comprises 2 distinct concepts: (1) noninvasive remote ischemic conditioning (RIC) using brief cycles of transient ischemia and reperfusion to an organ or tissue remote from the heart before (preconditioning) or during (perconditioning) ischemia and (2) ischemic postconditioning (PostC) via repetitive brief interruptions of coronary blood flow immediately after revascularization of the culprit lesion. [8] [9] [10] While both conditioning techniques demonstrated marked effects in experimental studies, 7, 11 investigations on surrogate markers in humans showed conflicting results. Lønborg et al 12 reported increased myocardial salvage assessed by cardiac magnetic resonance (CMR) imaging after PostC in patients with STEMI. In contrast, other studies including LIPSIA CONDITIONING did not reveal improved surrogate parameters of myocardial damage after PostC. [13] [14] [15] [16] [17] Evidence in support of a protective effect of RIC is provided by several randomized controlled trials and systematic meta-analyses. [18] [19] [20] [21] However, it is unclear whether these potential improvements in surrogate markers translate into beneficial clinical outcome. PostC failed to reduce all-cause mortality and hospitalization for heart failure in a large trial, 22 whereas RIC was associated with a reduction of cardiovascular events. 20, 23 Expanding previous conditioning protocols, the LIPSIA CONDITIONING trial 13 also evaluated the combination of RIC plus PostC and found a significantly increased myocardial salvage assessed by CMR imaging compared with conventional PCI. The aim of the present study was to investigate whether these additive protective effects result in a reduction of long-term adverse clinical events.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Design and Population
The present study is a post hoc long-term clinical follow-up analysis of the LIPSIA CONDITIONING trial, which was a prospective, randomized, open-label, controlled trial conducted at the University of Leipzig-Heart Center between April 2011 and May 2014. The detailed study protocol was reported previously. 13 In brief, patients with STEMI undergoing primary PCI were randomized in an 1:1:1 ratio to (1) combined intrahospital RIC and PostC in addition to PCI; (2) PostC alone in addition to PCI; or (3) conventional PCI. The random allocation to the treatment groups prevents a potential selection bias. RIC was performed by inflation of an upper arm blood pressure cuff to 200 mm Hg for 5 minutes followed by deflation for 5 minutes. Patients underwent 3 cycles of RIC with the first cycle starting immediately after randomization at the time of hospital admission and continuation of the protocol during transport to the catheterization laboratory and beginning of coronary angiography, which was not delayed by RIC. PostC was performed after primary PCI as follows: an angioplasty balloon was positioned at the site of the index lesion within 1 minute of reopening the infarct-related coronary artery and reinflated 4 times with low pressure (4-6 atm). Each reocclusion lasted for 30 seconds and was followed by 30 seconds of reflow. Complete reocclusion of the vessel was ensured by dye injection during balloon inflation.
Patients with STEMI (≥0.1 mV in ≥2 extremity leads or ≥0.2 mV in ≥2 precordial leads) undergoing primary PCI were eligible if symptoms lasted for <12 hours. Exclusion criteria were prior fibrinolysis, cardiogenic shock, pregnancy, participation in another trial, age <18 years, life expectancy <6 months, and contraindications for CMR. Primary PCI was performed according to standard clinical practice, and concomitant medications were prescribed as 
Novelty and Significance
What Is Known?
• Timely reperfusion of the culprit coronary artery is the most critical step of salvaging ischemic myocardium from impending infarction. However, prompt restoration of coronary flow by reopening the occluded infarct-related artery can itself paradoxically induce ischemiareperfusion injury.
• Experimental studies suggest that ischemic conditioning may prevent or attenuate reperfusion injury.
• Clinical data regarding the protective effects of ischemic conditioning are scarce and mainly based on surrogate markers of myocardial damage rather than clinical end points.
What New Information Does This Article Contribute?
• The combination of remote ischemic conditioning and postconditioning significantly reduces the incidence of major adverse cardiac events and new congestive heart failure in patients with ST-segmentelevation myocardial infarction.
• The impact of postconditioning alone is less pronounced with no difference in major adverse cardiac events and a nonsignificant reduction of heart failure events.
Experimental studies have demonstrated that ischemic conditioning may protect the myocardium from reperfusion injury. Investigations in humans showed promising results regarding surrogate markers of myocardial injury. However, it is unclear whether these improvements translate into beneficial clinical outcome. In our post hoc long-term analysis of a randomized trial in patients with ST-segment-elevation myocardial infarction, combined intrahospital remote ischemic conditioning and ischemic postconditioning in addition to primary percutaneous coronary intervention significantly reduced the incidence of major adverse cardiac events and new congestive heart failure compared with a control population undergoing conventional percutaneous coronary intervention. In contrast, ischemic postconditioning alone showed less pronounced effects with no difference in major adverse cardiac events and a nonsignificant reduction of heart failure as compared to controls. These findings suggest that cardioprotection, by combined intrahospital remote ischemic conditioning and ischemic postconditioning, in addition to stateof-the-art reperfusion therapy, reduces the risk of adverse clinical events following ST-segment-elevation myocardial infarction, particularly postinfarction heart failure.
recommended in current guidelines. 2, 13 The choice of the stent type and the use of thrombus aspiration or glycoprotein IIb/IIIa inhibitors were left to the operators' discretion.
The primary study end point and basis for sample size calculation was myocardial salvage index assessed by CMR imaging. Combined RIC and PostC resulted in a significantly greater myocardial salvage compared with the control group, whereas PostC alone failed to improve the CMR end point. 13 Clinical follow-up at 6 months showed similar event rates in the study groups.
The study protocol was approved by the local ethics committee, and the study was conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki. All patients gave written informed consent.
Clinical Long-Term Follow-Up and End Points
Posthospital follow-up was performed during regular outpatient visits and structured telephone interviews with patients, relatives, and treating physicians. Data were collected by blinded investigators and recorded in standardized case report forms. All events were verified via medical records and contact with the treating physicians and finally adjudicated by a clinical events committee unaware of the assigned treatment.
The clinical end point was a composite of cardiac death, reinfarction, and new congestive heart failure at long-term follow-up. To avoid double counting of patients with >1 event, each patient contributed only once to the composite major adverse cardiac events (MACE) end point. The analysis of the single components of the combined end point, however, included all observed events. Reinfarction was diagnosed in patients with clinical symptoms, new ST-segment changes, and increase in troponin T levels above the reference limit in patients with normalized values after the index event or of at least 50% from the last non-normalized measurement. New congestive heart failure was defined as any new diagnosis of congestive heart failure >24 hours after randomization with ≥1 of the following disorders necessitating treatment with diuretics: cardiogenic shock, pulmonary edema, or congestion on chest radiography, rales >1/3 from lung base (Killip class ≥2), pulmonary capillary wedge pressure >25 mm Hg; and dyspnea with oxygen saturation <90% without supplemental oxygen in the absence of a lung disease. Patients with heart failure <24 hours after randomization (n=5; RIC and PostC, n=2; PostC only, n=1; control group, n=2) were not included in the analysis. Cardiac death was defined as any death related to cardiogenic shock, sudden cardiac death, terminal heart failure, myocardial infarction, or lethal arrhythmias. Furthermore, we assessed the long-term rates of stroke or transient ischemic attack and the need for nonurgent repeat revascularization. Cerebrovascular events were defined according to current diagnostic criteria 24 and independently confirmed by a neurologist.
Statistical Analyses
All statistical analyses were performed according to the intention-totreat principle. Continuous data are reported as median and interquartile range (IQR). Categorical variables are presented as numbers and percentages. Differences between treatment groups were analyzed for MACE and for the single components of the composite end point. The χ 2 test was used for between-group comparisons. Furthermore, a time-to-event analysis was performed with the Kaplan-Meier method and log-rank testing. Odds ratios and hazard ratios with corresponding 95% CI are reported to illustrate differences. In case of a significant difference, the consistency of treatment effects were analyzed in predefined subgroups by sex, age (≤65 versus >65 years), infarct location, Killip class on admission (Killip class I versus II to IV), TIMI (Thrombolysis In Myocardial Infarction) flow pre-PCI (0 to II versus III), symptom onset to PCI time (≤3 versus >3 hours), size of the area at risk (≤20% versus >20%), use of aspiration thrombectomy, direct stenting, and administration of glycoprotein IIb/IIIa inhibitors. The Breslow-Day test was used to analyze the interaction between treatment arm and subgroup factors. Moreover, the independent predictive value of the assigned treatment approach about the respective end point was assessed in univariate and stepwise multivariate Cox regression analysis. Only significant predictors in univariate testing were included in the multivariate model. PostC only was additionally evaluated in the subgroup of patients with TIMI 0 or I flow before PCI. Furthermore, postdischarge MACE were assessed in an analysis which included only patients without events during the initial hospital stay. All statistical analyses were performed with SPSS software, version 23.0. A 2-tailed P<0.05 was considered statistically significant.
Results
During the inclusion period, 696 of 731 eligible consecutive patients with STEMI undergoing primary PCI were randomized to RIC and PostC (n=232), PostC only (n=232), or conventional PCI (n=232; Figure 1 ). In the combined RIC and PostC group, 193 patients (83%) underwent the complete RIC protocol of 3 cycles of ischemia and reperfusion whereas 35 patients (15%) underwent 2 cycles and 4 patients (2%) Figure 1 . Study flow chart. A total of 696 of 731 eligible patients with ST-segmentelevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) were randomized to remote ischemic conditioning (RIC) and ischemic postconditioning (PostC), PostC only, or control (n=232 patients in each study group). Long-term follow-up data were available in 672 patients (97%) after in median 3.6 y. ICD indicates implantable cardioverter defibrillator; PM, pacemaker; and RIC, remote ischemic conditioning. underwent 1 cycle. PostC was performed per protocol in 212 patients (91%) in the combined treatment group and in 225 patients (97%) in the PostC only group. Long-term follow-up was obtained in median 3.6 years after the index event (IQR, 2.9-4.2 years) in 97% of patients (Figure 1 ).
Clinical and Procedural Characteristics
Baseline clinical characteristics and cardiovascular risk factors were well balanced between the study groups ( Table 1) . The study cohort was predominantly male (73%) and had a median age of 63 years (IQR, 54-74 years). Angiographic characteristics and procedural success were similar in the 3 randomized groups and medical therapy at discharge did not differ either (Table 1) .
Long-Term Clinical Outcome
At long-term follow-up, a total of 103 MACE consisting of cardiac death, reinfarction, and new congestive heart failure were observed in 92 patients with 11 patients experiencing >1 event. Patients with heart failure events had a significantly reduced left ventricular ejection fraction (median 38%; IQR, 30%-45%), increased end-diastolic volumes (median 160 mL; IQR, 126-194 mL) and elevated NT-proBNP (N-terminal Pro-B-type natriuretic peptide) levels ranging from 756 to 21747 pg/mL. All events were heart failure with reduced ejection fraction. Detailed information about patients experiencing heart failure is provided in Table 2 .
MACE occurred in 10.2% of patients in the combined RIC and PostC group and in 16.9% in the control group (odds ratio, 0.56; 95% CI, 0.32-0.97; P=0.04; Table 3 ; Figure 2A ). While the rates of cardiac death (P=0.61) and reinfarction (P=0.75) were similar in both groups, the difference was driven by a significantly reduced rate of new congestive heart failure in the RIC and PostC group (2.7% versus 7.8%; odds ratio, 0.32; 95% CI, 0.13-0.84; P=0.02; Table 3 ; Figure 2B through 2D). In the combined treatment group, 1 of 6 heart failure events (16.7%) occurred during index hospitalization compared with 6 of 17 events (35.3%) in the control group (P=0.39). However, the majority of cases with new congestive heart failure in both treatment arms was readmitted to the hospital after discharge (Table 2) . Subgroup analyses confirmed the consistency of the results among all predefined subgroups (Figure 3) . Including clinical and angiographic characteristics as well as various parameters of reperfusion success and myocardial damage in a Cox regression model, combined RIC and PostC was identified as an independent predictor for the prevention of new congestive heart failure (hazard ratio, 0.35; 95% CI, 0. Figure 2A ). Analysis of the individual components of the composite primary end point revealed similar cardiac mortality (P=0.91), whereas the PostC group showed numerically higher rates of reinfarction (P=0.08) and a nonsignificant reduction of new congestive heart failure (P=0.05; Table 3 ; Figure 2B through 2D). Considering only patients with TIMI 0 or I flow before PCI, PostC only did not result in a reduction of long-term clinical events compared with the control group (Online Table I ).
Postdischarge MACE rates did not show significant differences between the study groups with a nonsignificant reduction of new congestive heart failure in both treatment arms (Online Table II ).
The frequency of cerebrovascular events consisting of stroke or transient ischemic attack was low and did not differ between the study groups (Table 3) . Likewise, no significant differences were observed about the need for nonurgent repeat coronary revascularizations (Table 3) .
Discussion
This post hoc analysis of a prospective, randomized study investigated the impact of different ischemic conditioning strategies on long-term clinical outcome in patients with STEMI. The main finding was that intrahospital RIC and PostC in addition to primary PCI significantly reduced the incidence of MACE and new congestive heart failure. In contrast, the impact of PostC alone in addition to primary PCI was less pronounced with no difference in MACE and a nonsignificant reduction of new heart failure events as compared to controls. Therefore, our data indicate that the additive protective effects of combined RIC and PostC may translate into improved clinical outcome.
Despite the success of urgent reperfusion therapy by primary PCI, acute mortality, and long-term morbidity resulting from chronic heart failure remain a major concern in patients with STEMI. 25 Consequently, there is a need for adjunctive therapy to prevent these adverse events. Although restoration of coronary blood flow is clearly the most effective treatment approach, it also contributes to infarct size expansion, a major determinant of patients' outcome, 3 by adding reperfusion injury on top of ischemic myocardial damage. 4, 5 The conditioning phenomenon was observed >3 decades ago and showed powerful effects to protect the myocardium from reperfusion injury in numerous experimental studies using preconditioning, perconditioning, and postconditioning protocols. 7, 11 However, subsequent translation from bench to bedside was slow and partially disappointing. Clinical proof-of-concept studies with surrogate end points (myocardial injury by biomarker release or cardiac imaging) reported predominantly promising initial results for both RIC and PostC. 16 Particularly RIC in addition to reperfusion was consistently associated with reduced infarct size after STEMI. 16 In contrast, neutral results in the 3 largest trials investigating PostC dampened hopes for a timely establishment into clinical practice. 13, [15] [16] [17] Furthermore, available data about clinical end points were sparse, had methodological limitations, and failed to prove a benefit after ischemic conditioning. Several clinical trials with improved study design and larger patient populations were published most recently. These investigations and the results of our study provide novel insights into the clinical impact of different conditioning approaches. In line with neutral results concerning surrogate markers of myocardial injury, PostC failed to prove a definite clinical benefit in these studies. The multicenter DANAMI-3-iPOST (Third Danish Study of Optimal Acute Treatment of Patients with STEMI Ischemic PostConditioning) trial randomized 1234 patients with STEMI and TIMI grade 0-1 flow to conventional PCI or additional PostC. 22 PostC did not reduce the rates of allcause death or hospitalization for heart failure after a median follow-up of 38 months. Similarly, PostC alone did not affect the occurrence of MACE during long-term follow-up in the present study and the reduction of new heart failure events did not reach statistical significance. The success of PostC has been associated with patient-related factors (age, sex), stenting technique (direct stenting versus predilatation), and the PostC algorithm itself (duration of the ischemia/reperfusion cycles, time between reperfusion and ischemic conditioning). 22, 26 These confounding factors are discussed as potential explanations for the neutral clinical results of routine PostC. 27 Of note, the 30-second PostC algorithm in the present study and in DANAMI-3-iPOST was chosen based on experimental data and a proof-of-concept study, which demonstrated increased myocardial salvage after STEMI. 12, 13, 22, 28 However, the approach deviated from the originally proposed PostC protocol with 60-second cycles. 10 A potential clinical benefit of alternative PostC protocols or in selected patients with STEMI remains to be investigated. While previous studies did not raise any safety concerns about PostC, our analysis showed an increased rate of reinfarction in the PostC group. Although these events were not exclusively related to target lesion failure and patients in the combined treatment group underwent the identical PostC protocol without an increased risk of reinfarction, the safety of PostC deserves further observation in future studies.
Clinical data on RIC in patients with STEMI provide a more optimistic outlook. Promising preliminary clinical results in smaller studies 29 were recently confirmed by metaanalyses of randomized controlled trials, which found a significant reduction of MACE after additional RIC in patients with STEMI, primarily caused by a lower incidence of postinfarction heart failure. 19, 20 The RIC-STEMI (RIC in STEMI as an adjuvant to primary angioplasty) trial randomized 448 STEMI patients to conventional PCI or additional RIC. 23 The study was designed for the primary clinical end point of cardiac death or hospitalization for heart failure albeit the expected event rates were not achieved which limits the actual statistical power of the analysis. However, the results after a median follow-up of 2.1 years indicate a significant reduction of the combined end point as well as its individual components. 23 Our study expands these findings by showing a reduction of long-term clinical events in the RIC and PostC group driven by a significant reduction of new congestive heart failure during follow-up. Of note, unlike previous studies, we did not treat patients with RIC alone. It remains, therefore, unclear whether cardioprotection was mainly attributable to RIC or because of synergistic effects of combining RIC and PostC. Nevertheless, there seems to be sound evidence that RIC reduces myocardial damage in patients with STEMI, which translates into improved clinical outcome by preventing progression to heart failure. Furthermore, RIC is safe, noninvasive, easily feasible, and cost-effective. 30 However, the results of a large, prospective, randomized clinical trial (CONDI-2/ERIC-PPCI; URL: http://www.clinicaltrials.gov. Unique identifier: NCT02342522; n=5400 patients with STEMI; primary end point: cardiac death and hospitalization for heart failure at 12 months) 31 are expected soon and should be awaited before discussing an implementation in clinical practice. Novel data might also improve patient selection by providing insights about STEMI subpopulations deriving the most benefit from RIC (eg, patients with short/long ischemic time, large area at risk, or fully occluded coronary arteries without collateral circulation). Subgroup analyses in our study showed some trends concerning more pronounced treatment effects in younger, male patients with a large area at risk albeit statistical differences were not observed, maybe because of the small sample sizes in the respective subgroups. Further advances in cardioprotection with RIC might be achieved by optimizing the conditioning algorithm (eg, number and duration of ischemia/reperfusion cycles) and its timing (eg, prehospital start with conditioning). 32 However, improvement of the conditioning process requires a better understanding of the mechanisms underlying myocardial reperfusion injury and cardioprotection by RIC. Therefore, additional experimental studies focusing on the involved signal transduction pathways are also needed to optimize ischemic conditioning.
Limitations
The present study is limited by its post hoc nature and the sample size, which was calculated based on the primary end point of the LIPSIA CONDITIONING trial (myocardial salvage index in CMR imaging) rather than clinical events. 13 In this regard, particularly the multiple subgroup analysis has limited statistical power and exploratory character. Furthermore, patients with contraindications for CMR (eg, with cardiogenic shock or metallic implants) were not included in the study and the findings cannot be extrapolated to these patient populations. Some patients in the treatment arms did not undergo the conditioning process as intended with a premature termination of RIC before completing 3 cycles of ischemia/reperfusion or omission of PostC. The frequency and reasons for deviations from the study protocol have been provided in detail previously. 13 According to previous STEMI guidelines, aspiration thrombectomy was used liberally in our study. Meanwhile, this recommendation has been revised and thrombus aspiration is no longer used routinely in patients with STEMI. Systematic follow-up evaluation of left ventricular function and volumes, which could have provided mechanistic insights into the pathophysiologic effects of ischemic conditioning, was not performed. Finally, RIC alone was not tested in our study, as already discussed, and the population consisted predominantly of male patients.
Conclusions
Cardioprotection by combined intrahospital RIC and PostC in addition to primary PCI significantly reduced the rate of MACE mainly driven by a reduction of new congestive heart failure after STEMI when compared with conventional PCI. In contrast, PostC alone in addition to primary PCI had less pronounced effects with a nonsignificant reduction of new heart failure events. More data from adequately powered clinical studies are needed to optimize conditioning protocols and improve patient selection as prerequisites for an implementation in clinical practice.
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